| bimatoprost / Generic mfg. |
ACTRN12610000199011: Comparative Study of the Efficacy and Safety of two presentations of Bimatoprost 0.03% available in Brazil: Glamigan(registered trademark) and Lumigan(registered trademark). |
|
|
| Not yet recruiting | 4 | 54 | | | Ophthalmology Department of the State University of Campinas, Germed Pharma ltda | glacoma, ocular hypertension | | | | |
NCT00847483: Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US |
|
|
| Completed | 4 | 375 | US | latanoprost 0.005% ophthalmic solution, Xalatan, Travoprost 004% sterile ophthalmic solution, Travatan, Bimatoprost .03% sterile ophthalmic solution, Lumigan | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Glaucoma, Ocular Hypertension | 08/02 | 08/02 | | |
NCT01655758: 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension |
|
|
| Completed | 4 | 61 | Europe | 0.5% timolol, timoptol (MSD), timolol-dorzolamide fixed combination, cosopt (MSD), Latanoprost, xalatan (pfizer), Travoprost, travatan (Alcon), Bimatoprost, lumigan (Allergan) | University of Parma | Ocular Hypertension | 12/03 | 02/04 | | |
NCT00355446: Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous. |
|
|
| Completed | 4 | 48 | US | Bimatoprost 0.03% | Indiana University School of Medicine | Cataract | | 10/04 | | |
NCT00329095: An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance |
|
|
| Completed | 4 | 60 | US | travoprost, latanoprost, or bimatoprost, Additional ocular hypotensive medication | Robin, Alan L., M.D. | Glaucoma, Ocular Hypertension | | 04/06 | | |
2006-002941-35: EFFECTS OF PROSTAGLANDIN COMPOUNDS ON CONJUNTIVAL MELANOGENESIS: AN IMPRESSION CITOLOGY AND TYROSINASE MARKERS STUDY |
|
|
| Completed | 4 | 80 | Europe | Eye drops, solution, XALATAN*GTT OFT 1FL 0,005% 2,5, XALACOM*GTT OFT 1FL 2,5ML, TRAVATAN*GTT OFT 1FL 40MCG/ML, LUMIGAN*COLL FL 3ML, TIMOPTOL*COLL FL 3ML 0,5%, CARTEOL*COLL FL 5ML 2% | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | EVALUATION OF CONJUNTIVAL MELANOGENESIS IN HEALTHTY VOLOUNTEERS AND GLAUCOMATOUS PATIENTS IN THERAPY WITH PROSTAGLANDIN COMOUNDS | | | | |
2004-002979-16: A Six-Week/Six-Week, Prospective, Randomised, Masked, Cross over, Primary Therapy Study comparing IOP Lowering Effects of Lumigan® and Xalatan® in Subjects with Primary Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation glaucoma & Pigment dispersion |
|
|
| Completed | 4 | 100 | Europe | LUMIGAN®, XALATAN®, Eye drops, solution, LUMIGAN®, XALATAN® | CARDIFF UNIVERSITY | Primary open-angle glaucoma, Ocular hypertension, Pseudoexfoliation glaucoma or Pigment dispersion | | | | |
NCT00348023: Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension |
|
|
| Completed | 4 | | US | Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5% | Innovative Medical | Glaucoma | | | | |
| Completed | 4 | 34 | US | bimatoprost 0.03%, dorzolamide 2%/timolol maleate 0.5% fixed combination, placebo | Pharmaceutical Research Network | Open-Angle Glaucoma | | 05/07 | | |
NCT00347841: Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost |
|
|
| Completed | 4 | | US | Bimatoprost 0.03%, Latanoprost | Innovative Medical | Glaucoma | | | | |
NCT00347802: Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004% |
|
|
| Completed | 4 | | US | Bimatoprost 0.03%, Travoprost 0.004% | Innovative Medical | Glaucoma | | | | |
NCT00348062: A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | | US | Bimatoprost | Innovative Medical | Glaucoma | | | | |
NCT00440011: Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% |
|
|
| Completed | 4 | 266 | US | bimatoprost 0.03% eye drops, Lumigan®, travoprost 0.004% eye drops, Travatan® | Allergan | Glaucoma, Ocular Hypertension | 10/07 | 10/07 | | |
NCT00539526: Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues |
|
|
| Completed | 4 | 106 | US | Bimatoprost 0.03%, Lumigan®, travoprost 0.004%, Travatan® Z, latanoprost 0.005% eye drops, Xalatan® | Allergan | Open Angle Glaucoma, Ocular Hypertension | 07/08 | 09/08 | | |
NCT00541242: Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | 586 | US | bimatoprost 0.03% eye drops, latanoprost = Xalatan®, bimatoprost = Lumigan®, latanoprost 0.005% eye drops, Xalatan® | Allergan | Ocular Hypertension, Glaucoma | 08/08 | 08/08 | | |
NCT01229423: Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects |
|
|
| Completed | 4 | 62 | RoW | bimatoprost 0.03%, LATISSE® | Allergan | Eyelash Hypotrichosis | 06/10 | 10/10 | | |
NCT00958035: Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis |
|
|
| Completed | 4 | 89 | US | bimatoprost ophthalmic 0.03% solution, LATISSE®, vehicle sterile solution (placebo) | Allergan | Hypotrichosis | 07/10 | 08/10 | | |
NCT01202513: Topical Bimatoprost Solution 0.03%in Stable Vitiligo |
|
|
| Withdrawn | 4 | 20 | RoW | Bimatoprost 0.03% topical ophthalmic solution | Gian Sagar Medical College and Hospital | Vitiligo, Repigmentation | 11/10 | 11/10 | | |
| Completed | 4 | 1137 | Canada | Bimatoprost 0.01%, LUMIGAN® RC | Allergan | Glaucoma, Primary Open Angle, Ocular Hypertension | 03/11 | 03/11 | | |
NCT00705757: The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye |
|
|
| Completed | 4 | 89 | US | latanoprost, Xalatan 0.005%, bimatoprost, Lumigan 0.03%, travoprost, Travatan 0.004% | Summa Health System | Glaucoma, Application Site Pigmentation Changes | 04/11 | 04/11 | | |
LOTUS, NCT02061683: A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension |
|
|
| Completed | 4 | 263 | RoW | Bimatoprost 0.03%, LUMIGAN® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 06/11 | 06/11 | | |
NCT01253902: Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | 164 | US, Canada | bimatoprost ophthalmic solution 0.01%, Lumigan® 0.01%, Lumigan® RC, travoprost ophthalmic solution 0.004%, Travatan Z®, latanoprost ophthalmic solution 0.005%, Xalatan® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 10/11 | 10/11 | | |
NCT01387906: Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo |
|
|
| Completed | 4 | 20 | US | topical bimatoprost, bimatoprost, Latisse, eyebrows | Kenneth Beer, Allergan | Hypotrichosis | 03/12 | 06/12 | | |
NCT01448525: Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence |
|
|
| Completed | 4 | 88 | US | bimatoprost ophthalmic solution 0.03%, LATISSE®, bimatoprost vehicle solution | Allergan | Hypotrichosis | 04/12 | 04/12 | | |
NCT01464424: Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) |
|
|
| Completed | 4 | 84 | US | Travoprost 0.004% ophthalmic solution, TRAVATAN® Z, Bimatoprost 0.01% ophthalmic solution, LUMIGAN® | Alcon Research | Glaucoma, Ocular Hypertension, Open-Angle Glaucoma | 06/12 | 06/12 | | |
NCT01271686: 24-hour IOP-lowering Effect of 0.01% Bimatoprost |
|
|
| Completed | 4 | 16 | US | 0.01% bimatoprost, Lumigan 0.01% | University of California, San Diego | Intraocular Pressure, Glaucoma, Ocular Hypertension | 10/12 | 10/12 | | |
NCT01525173: A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension |
|
|
| Completed | 4 | 137 | US | 0.1% brimonidine tartrate ophthalmic solution, ALPHAGAN® P, 0.01% bimatoprost ophthalmic solution, LUMIGAN®, 0.2% hypromellose lubricant eye drops, GenTeal ®, latanoprost 0.005% ophthalmic solution | Allergan | Glaucoma, Ocular Hypertension | 10/12 | 10/12 | | |
NCT01023841: Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children |
|
|
| Completed | 4 | 71 | US, RoW | bimatoprost ophthalmic solution 0.03%, LATISSE®, Vehicle Sterile Solution | Allergan | Eyelash Hypotrichosis, Alopecia Areata | 11/12 | 11/12 | | |
LOTUSDI, NCT02020512: A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension |
|
|
| Completed | 4 | 87 | RoW | 0.03% Bimatoprost, LUMIGAN® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 12/12 | 12/12 | | |
NCT01594970: A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) |
|
|
| Completed | 4 | 800 | RoW | Bimatoprost 0.01%, LUMIGAN® 0.01% | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 01/13 | 01/13 | | |
2010-024272-26: Comparison between the effects on ocular pressure of Bimatoprost 0.01% and Timolol 0.5% during the day and night Confronto tra gli effetti sulla pressione degli occhi del Bimatoprost 0.01% e Timololo 0.5% di giorno e di notte |
|
|
| Completed | 4 | 40 | Europe | Eye drops, solution, LUMIGAN*COLL FL 3ML 0,1MG/ML, TIMOLOLO NOVARTIS*OFT 5ML 0,5% | IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS, Allergan | glaucoma and ocular hypertension glaucoma ed ipertensione oculare, ocular hypertension and optic nerve degeneration due to ocular pressure pressione alta degli occhi e degenerazione del nervo ottico dovuta alla pressione intraoculare, Diseases [C] - Eye Diseases [C11] | | | | |
NCT01493427: Efficacy of Changing to TRAVATAN® From Prior Therapy |
|
|
| Completed | 4 | 202 | Europe | Travoprost 0.004%, TRAVATAN® BAK-free | Alcon Research | Open-Angle Glaucoma, Ocular Hypertension | 02/13 | 02/13 | | |
2011-003816-21: A clinical trial to evaluate wether Travatan is effective and well tolerated by patients that were previously treated with latanoprost or bimatoprost |
|
|
| Completed | 4 | 200 | Europe | TRAVATAN, Eye drops, solution, TRAVATAN | S.A. Alcon-Couvreur N.V, Alcon Research, Ltd, ALCON RESEARCH, LTD., Alcon Research, Ltd, ALCON RESEARCH LTD | Open angle Glaucoma Ocular Hypertension, Glaucoma Ocular Hypertension, Diseases [C] - Eye Diseases [C11] | | | | |
| Completed | 4 | 47 | Europe | Brinzolamide 1% / timolol 0.5% Fixed Combination, AZARGA®, Habitual prostaglandin monotherapy, Latanoprost, Travoprost, Bimatoprost, Tafluprost | Alcon Research | Glaucoma, Ocular Hypertension | 04/13 | 04/13 | | |
NCT01547598: Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction |
|
|
| Completed | 4 | 135 | Canada | travoprost ophthalmic solution 0.004%, Travatan® Z, travoprost 0.004% / timolol 0.5% combination ophthalmic solution, DuoTrav®, Bimatoprost ophthalmic solution 0.01%, LUMIGAN® RC | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 07/13 | 07/13 | | |
NCT01937312: Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue |
|
|
| Completed | 4 | 282 | US | Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, SIMBRINZA® Suspension, Vehicle, Prostaglandin analogue, TRAVATAN Z®, LUMIGAN®, XALATAN® | Alcon Research | Ocular Hypertension, Open Angle Glaucoma | 05/14 | 05/14 | | |
| Completed | 4 | 104 | Europe | Travoprost 0.004% ophthalmic solution, TRAVATAN®, Bimatoprost 0.01% ophthalmic solution, LUMIGAN® | Alcon Research | Glaucoma, Ocular Hypertension | 06/14 | 06/14 | | |
NCT01891487: Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows |
|
|
| Completed | 4 | 33 | US | Track A, Active study drug, Bimatoprost 0.03% solution, Track B, Placebo control group, Refresh Tears | ATS Clinical Research, Allergan | Hypotrichosis | 09/14 | 01/15 | | |
NCT01881126: An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | 93 | Canada | bimatoprost 0.01%, Lumigan® RC, Lumigan®, travatan 0.004%, Travatan Z®, timolol 0.5%, Timolol Maleate-EX, Timolol GFS, hypromellose 0.3%, GenTeal® | Allergan | Glaucoma, Ocular Hypertension | 10/14 | 10/14 | | |
NCT02097719: Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | 100 | US | bimatoprost 0.01%, Lumigan® RC, Lumigan®, travoprost 0.004%, Travatan Z®, timolol 0.5%, Timolol Maleate-EX, Timolol GFS, hypromellose 0.3%, GenTeal® | Allergan | Glaucoma, Ocular Hypertension | 12/14 | 12/14 | | |
NCT01975714 / 2013-003490-10: Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study |
|
|
| Completed | 4 | 67 | Europe | Preservative-free latanoprost, Monoprost, Preservative-free bimatoprost | Association for Innovation and Biomedical Research on Light and Image, European Vision Institute Clinical Research Network | Glaucoma, Ocular Hypertension | 02/15 | 02/15 | | |
NCT02176356: Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) |
|
|
| Completed | 4 | 116 | US | onabotulinumtoxinA, botulinum toxin Type A, bimatoprost ophthalmic solution 0.03%, LATISSE®, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC | Allergan | Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold | 05/15 | 05/15 | | |
2014-000404-10: Effectiveness in the ocular pressure, tolerability and influence in the ocular surface of bimatoprost and tafluprost pod in patients with glaucoma and ocular hipertension Eficacia sobre la presión intraocular, tolerancia e influencia sobre la superficie ocular del Bimatoprost monodosis y Talfuprost monodosis en pacientes con glaucoma e hipertension ocular |
|
|
| Ongoing | 4 | 60 | Europe | Bimatoprost, Tafluprost, Eye drops | Hospital Clinico San Carlos, Allergan Inc | Glaucoma andr ocular hypertension Glaucoma e hipertension ocular, Ocular hypertension Tension ocular alta, Diseases [C] - Eye Diseases [C11] | | | | |
| Completed | 4 | 31 | Europe | Bimatoprost, Trade Name Lumigan. MA number: EU/1/02/205/001-002. ATC Code: S01EE03, Eye drop solution, 1 drop daily, Hypromellose Ph Eur 0.3g in 100ml, Sodium chloride, Potassium chloride, Borax, Boric acid, Benzalkonium chloride solution, Purified water, Sodium hydroxide solution (to adjust pH), Hydrochloric acid | Cardiff University, National Institute for Social Care and Health Research | Graves' Ophthalmopathy | 03/16 | 03/16 | | |
| Completed | 4 | 379 | Europe | Monoprost, Latanoprost 0.005%, Lumigan 0.01%, Bimatoprost 0.1mg/ml, Lumigan 0.03% Unit Dose, Bimatoprost 0.3mg/ML | Laboratoires Thea | Primary Open Angle Glaucoma, Ocular Hypertension | 07/16 | 07/16 | | |
NCT01927406: The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. |
|
|
| Withdrawn | 4 | 0 | US | Prostaglandin Analog, Bimatoprost, Travoprost Z, Tafluprost, Latanoprost, Timolol, Timolol maleate 0.5% | Stanford University | Thyroid Eye Disease, Ocular Hypertension, Glaucoma | 12/16 | 12/16 | | |
| Completed | 4 | 806 | Europe, RoW | bimatoprost 0.01% ophthalmic solution, LUMIGAN® 0.01%, LUMIGAN 0.1 mg/ml, bimatoprost 0.03% ophthalmic solution, LUMIGAN® 0.03%, LUMIGAN 0.3 mg/ml | Allergan | Glaucoma, Ocular Hypertension | 12/16 | 12/16 | | |
SPORTII, NCT02471105: Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml |
|
|
| Unknown status | 4 | 67 | Europe | Preserved Bimatoprost 0.01%, BIMMD, Lumigan 0.01 %, Tafluprost Unit Dose Preservative Free 15microgram/ml, TUDPF, Saflutan | Universitaire Ziekenhuizen Leuven, Allergan | Ocular Hypertension, Glaucoma | 05/17 | 12/17 | | |
2014-004442-10: Investigation of intraocular pressure and tolerability of Bimatoprost 0.1% and Tafluprost Unit Dose Preservative Free 15 microgram/ml. |
|
|
| Completed | 4 | 67 | Europe | Eye drops, solution, Eye drops, suspension in single-dose container, Preservatived Bimatoprost, Lumigan 0.1 mg/ml, Tafluprost Unit Dose Preservative Free | UZ Leuven, Allergan | Ocular hypertension and glaucoma, Ocular hypertension and glaucoma, Diseases [C] - Eye Diseases [C11] | | | | |
| Completed | 4 | 290 | US | Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, SIMBRINZA® suspension, Brinz/brim vehicle, Prostaglandin analogue, TRAVATAN® PQ (Travoprost ophthalmic solution with PQ, 0.004%), LUMIGAN® (Bimatoprost ophthalmic solution, 0.01%), XALATAN® (Latanoprost ophthalmic solution, 0.005%) | Alcon Research | Open-Angle Glaucoma, Ocular Hypertension | 02/18 | 02/18 | | |
NCT01535768: Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves |
|
|
| Unknown status | 4 | 150 | Canada | Aqueous Suppressant Eye Drops, Timoptic, Trusopt, Azopt, Alphagan-P, Xalatan, Travatan Z, Lumigan, Diamox | Credit Valley EyeCare, Canadian Glaucoma Clinical Research Council | Glaucoma | 06/18 | 06/20 | | |
2013-000581-10: Examining the effects of eye drops on changes in inflammation on the surface of the eye |
|
|
| Completed | 4 | 100 | Europe | latanoprost, travaprost, bimatoprost, tafluprost, Timolol maleate, Brimonidine tartrate, Brinzolamide, Dorzolamide hydrochloride, pilocarpine hydrochloride, Pilocarpine nitrate, N/A, Eye drops, solution, Eye drops, , Xalatan, Travatan, Lumigan, Saflutan, Timptol, Trusopt, Pilocarpine hydrochloride, N/A | Nottingham University NHS Trust | Glaucoma is the condition that is being treated by these eye drops - however the study is aimed at measuring the amount of inflammation that develops on the surface of the eye when these drops are used, Diseases [C] - Eye Diseases [C11] | | | | |
NCT02571712: Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 4 | 750 | RoW | bimatoprost 0.03% plus timolol 0.5%, GANFORT® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 06/18 | 06/18 | | |
NCT03487042: Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo |
|
|
| Unknown status | 4 | 40 | NA | Bimatoprost 0.03% ophthalmic solution, Narrow band ultraviolet rays B, Fractional carbon dioxide laser | Assiut University | Generalized Vitiligo | 12/19 | 12/19 | | |
NCT06761313: Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma |
|
|
| Active, not recruiting | 4 | 40 | RoW | Triple combination formula, Maleate Timolol 0.5%, Brimonidine Tartarate 0.2%, Bimatoprost 0.03%, Bimatoprost .03% sterile ophthalmic solution, Timolol Maleate 0.5%, Brimonidine Tartarate 0.2%, Bimatoprost 0.03% | Federal University of São Paulo | Glaucoma, Quality of Life (QOL) | 12/24 | 02/25 | | |
| Recruiting | 4 | 48 | | Use bimatoprost ;Use travoprost ;Use latanprost ;Use tafluprost | West China Hospital of Sichuan University; West China Hospital of Sichuan University, 2019 West China Clinical Medical College of Sichuan University /West China Hospital Resident/Specialist Scientific Research Fund | Glaucoma | | | | |
NTG, NCT04981886: Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma |
|
|
| Not yet recruiting | 4 | 115 | US | Netarsudil Ophthalmic, Rhopressa, Bimatoprost Ophthalmic, Lumigan | Salus University | Normal Tension Glaucoma | 07/22 | 08/22 | | |
NCT06369077: How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? |
|
|
| Terminated | 4 | 36 | US | dorzolamide/timolol, latanoprost, timolol/brimonidine/dorzolamide/bimatoprost | CT Glaucoma Associates | Glaucoma, Open-Angle, Glaucoma; Drugs | 07/24 | 07/24 | | |
